

MEETING AT B.T.S. on 4.12.84

Present: Dr. L. Tovey  
Dr. A. Robinson  
Dr. R. J. Hutchinson  
Dr. L.M. Swinburne  
Dr. D. L. Barnard  
Dr. M. W. McEvoy  
Dr. L. Parapia-

*Handwritten notes:*  
Al  
M. W. McEvoy

HEAT TREATED FACTOR VIII

Although there is no proof or guarantee of its safety with regards to AIDS, it was agreed that on theoretical grounds heat-treated material was likely to be safer than non-treated material. However Dr. McEvoy and Dr. Parapia agreed that they felt that NHS material was preferable to heat-treated American supplies. Dr. Barnard and Dr. Swinburne were in favour of heat-treated material from either source, but at the moment there is no hard evidence on which to base the choice.

After reviewing the financial position:

- 1) It was agreed that no more untreated Factor VIII should be purchased. Existing stocks were low.
- 2) Centres would continue to use existing stocks of Elstree factor VIII or cryoprecipitate.
- 3) No further decisions can be made until after a meeting of Reference Centre Directors and Dr. Iano have been held next week. It is hoped that this will result in a statement of policy, and, more details of the plan to heat treat NHS Factor VIII, and how this will affect the supply position in the next few months.

Data collected suggest that the total utilisation for the year will be about 5.1 million units.

From usage to date, subtracting existing stocks, if deliveries of Elstree material continue at the present rate, there would be a deficit of 230,000 units which would need to be filled by purchased heat-treated material.

A further meeting was arranged for Tuesday 18th December at the B.T.S. at 4 p.m.

GRO-C